Health Care & Life Sciences » Pharmaceuticals | Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
677.50
679.70
684.30
684.20
687.00
685.20
Gross Income
677.50
679.70
684.30
684.20
687.00
685.20
SG&A Expense
12,350.50
16,131.70
23,969.50
23,827.80
13,034.50
7,369
EBIT
13,027.90
16,811.40
24,653.80
-
13,721.50
8,054.20
Unusual Expense
14,671.10
6,562.70
146.60
82.60
20.00
825
Non Operating Income/Expense
-
-
-
-
152.40
-
Pretax Income
27,697.70
10,243.00
24,502.30
24,427.30
13,517.80
8,179.40
Consolidated Net Income
27,697.70
10,243.00
24,502.30
24,427.30
13,517.80
8,153.10
Net Income
27,697.70
10,243.00
24,502.30
24,427.30
13,517.80
8,153.10
Net Income After Extraordinaries
27,697.70
10,243.00
24,502.30
24,427.30
13,517.80
8,153.10
Net Income Available to Common
28,886.40
10,243.00
24,502.30
28,859.50
13,531.90
8,153.10
EPS (Basic)
0.22
0.06
0.13
0.12
0.04
0.02
Basic Shares Outstanding
132,000.80
175,828.00
195,661.90
233,849.60
369,231.50
382,338.50
EPS (Diluted)
0.22
0.06
0.13
0.12
0.04
0.02
Diluted Shares Outstanding
132,000.80
175,828.00
195,661.90
233,849.60
369,231.50
382,338.50
EBITDA
12,350.50
16,131.70
23,969.50
23,827.80
13,034.50
7,369
Non-Operating Interest Income
1.30
5.60
4.90
2.10
31.30
19.60
Preferred Dividends
1,188.60
-
-
4,432.20
14.10
-

About Provectus Biopharmaceuticals

View Profile
Address
10025 Investment Drive
Knoxville Tennessee 37932
United States
Employees -
Website http://www.provectusbio.com
Updated 07/08/2019
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.